InvestorsPress Corporate
  1. Home
  2. Laboratory Diagnostics
  3. Assays by Diseases and Conditions
  4. Liver Fibrosis Assays 
  5. ELF Test Educational Videos
  6. Multidisciplinary Approach in the NAFLD/NASH Patient Care Pathway

Multidisciplinary Approach in the NAFLD/NASH Patient Care Pathway

Dr. Manuel Romero-Gómez
Professor of Medicine
UCM Digestive Diseases

Virgen del Rocío University Hospital; SeLiver group at Institute of Biomedicie of Seville (IBIS), University of Seville, Sevilla, Spain

|2021-12-10

There is a significant push within the medical community to devise simpler, more cost-efficient ways to assess and monitor NAFLD/NASH patients. An understanding of the disease across specialties and the use of noninvasive tests can help.

In this 5-minute video, Dr. Romero-Gómez discusses the need for a multidisciplinary approach in the NAFLD/NASH patient care pathway and how noninvasive tests like the Enhanced Liver Fibrosis (ELF™) Test can help.

Dr. Gomez

About Manuel Romero-Gómez, MD

Manuel Romero-Gómez, MD, is a professor of medicine at the University of Seville and director of the Digestive, Liver and Inflammatory Diseases Program at the Institute of Biomedicine of Seville and UCM Digestive Diseases at Virgen del Rocio University Hospital, Seville, Spain.

Prof. Romero-Gómez has published more than 300 peer-reviewed papers on gastrointestinal and liver diseases. He has 10 registered patents and has participated as a principal investigator in more than 20 competitive grants for research. He serves as coordinator of the Spanish Registry of NAFLD/NASH and co-coordinator of the EASL-supported European Registry of NAFLD. In 2016, he was awarded the Medal of The City of Seville.

The products/features mentioned here are not commercially available in all countries. Their future availability cannot be guaranteed.


In the U.S., the ELF Test is indicated as a prognostic marker in conjunction with other laboratory findings and clinical assessments in patients with advanced fibrosis (F3 or F4) due to nonalcoholic steatohepatitis (NASH) to assess the likelihood of progression to cirrhosis and liver-related clinical events.